EDITORIAL SECTION

Articles

Oligonucleotide Manufacturing: Scaling the Next Generation of Medicines

For most of their history oligonucleotides were manufactured the way specialty chemicals are made small batches high cost per gram and patient populations small enough that supply was rarely the limiting factor

Single-Use Technologies: Accelerating Flexible Biopharmaceutical Manufacturing

For most of the past two decades the case for singleuse technologies in biopharmaceutical manufacturing was argued in the language of the plant Disposable bags and flow paths removed cleaninplace and steaminplace loops shortened turnarounds and allowed engineers to stand up a suite without a validation campaign measured in seasons That argument has been won Disposable systems now appear at every s...

Adapting to the Post-Brexit Pharma Environment: Strategies for Success

The pharmaceutical industry has undergone significant changes following the United Kingdoms departure from the European Union commonly known as Brexit This historic event has introduced new challenges and opportunities for pharmaceutical

The Impact of Digital Health Technologies on Patient Outcomes

It is also noteworthy that the structure of the healthcare system has shifted rather dynamically in the past few years primarily because of the integration of digital health solutions Such developments

Genetic Testing in Mainstream Medicine: Driving Precision, Prevention, and Population Health

Healthcare systems globally are shifting toward valuebased care where reimbursement is tied to outcomes not procedures Genetic testingparticularly multigene panels and polygenic risk scores is emerging as a highimpact enabler of early intervention and targeted prevention reducing longterm costs and improving clinical outcomes

Strategic Synthesis: Shift to Continuous Manufacturing in Pharmaceuticals

The pharmaceutical industry is at a decisive inflection point necessitated by a move away from legacy batch processing toward Continuous Manufacturing CM This transition is no longer a peripheral innovation but a core strategic imperative for organizations seeking to maintain global competitiveness and uphold the highest standards

Techno Trends

Alume Biosciences Secures FDA Breakthrough Therapy Designation for Bevonescein

Alume Biosciences has received Breakthrough Therapy Designation BTD from the US Food and Drug Administration FDA for bevonescein an investigational fluorescent drug being developed to support realtime nerve visualisation during head and neck surgery in adults Bevonescein is an intravenous fluorescent peptidedye conjugate that binds to nerve tissue

Projects

SK pharmteco Plans More Than US$200 Million Investment in Small Molecule and Peptide Manufacturing

SK pharmteco is planning a fiveyear investment of more than US million to expand and modernise its pharmaceutical development and manufacturing operations in the United States The programme will strengthen capabilities for small molecules and peptides while supporting a more

Research Insights

A drug repurposing screen reveals dopamine signaling as a candidate therapeutic pathway for PIGA-CDG

PIGACDG is a congenital disorder of glycosylation caused by pathogenic partial lossoffunction variants in the PIGA gene PIGA encodes an enzyme responsible for the catalytic transfer of Nacetylglucosamine

whitepaper

Post-Translational Modifications in Drug Discovery: From Molecular Regulation to Clinical Impact

For decades the central dogma of molecular biology has anchored our understanding of cellular function DNA to RNA to protein But this linear view is incomplete A growing body of evidence shows that much of biologys